针对G9a/GLP的小分子化合物:最近的进展和前景
Qiangsheng Zhang1, Lu Li2, Siyan Li3
1School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, China.
European journal of medicinal chemistry
|March 23, 2025
概括
针对G9a/GLP的小分子抑制剂,在癌症等疾病中至关重要,已经取得了重大进展. 这篇评论详细介绍了它们的发现,设计和开发,为制药研究提供了见解.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 基因组甲基转移酶G9a/GLP与包括瘤,纤维化和疟疾在内的疾病有关.
- 自2007年以来,已开发出40多种G9a调节剂,针对这种酶家族.
研究的目的:
- 系统地审查针对G9a/GLP的小分子抑制剂.
- 分析G9a/GLP调制器的发现方法,设计策略和开发挑战.
主要方法:
- 关于G9a/GLP抑制剂的文献综述.
- 基于结合部位 (SAM竞争性,基质竞争性) 和机制 (可逆性,不可逆性,双重,降解剂) 的抑制剂的分类.
- 分析结构优化,结合方式,生物活性和药理动力学.
主要成果:
- 根据结合部位和作用机制对G9a/GLP抑制剂进行分类.
- 小分子发现,设计和优化策略的详细概述.
- 对各种G9a/GLP调节剂的生物活性和药理动力学数据的汇编.
结论:
- 在开发G9a/GLP的小分子抑制剂方面取得了重大进展.
- 该审查为未来针对G9a/GLP的药物开发所面临的挑战和机遇提供了有价值的见解.
更多相关视频
04:48A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
Published on: July 10, 2018
9.2K
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
13.6K
相关概念视频
GTPases and their Regulation
8.2K
Guanine nucleotide-binding proteins (G-proteins), also known as GTPases, are a superfamily of proteins that regulate many cellular processes, such as cell signaling, vesicular transport, and the regulation of cell shape and motility. Mutation or dysfunction of these proteins can lead to disease. There are around 40,000 known G-proteins that can broadly be classified into two groups ‒ small G-proteins consisting of a single domain and large multi-domain G-proteins.
Large G-proteins,...
Large G-proteins,...
8.2K
Glucagon-like Receptor Agonists
277
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
277
Targets for Drug Action: Overview
5.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
5.9K
G Protein-coupled Receptors
11.0K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
11.0K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
